Du är här

2016-02-12

Bionor Pharma ASA: Bionor Pharma ASA - Extraordinary General Meeting

BIONOR PHARMA ASA

STOCK EXCHANGE ANNOUNCEMENT

Bionor Pharma ASA - Extraordinary General Meeting

(Oslo, Norway, 12 February 2016) Bionor Pharma ASA (OSE:BIONOR), a
biopharmaceutical company focused on advancing a functional cure for HIV, has
received a request from Lars Høie and certain other shareholders, who jointly
hold approximately 30 per cent of the share capital in the company, that an
extraordinary general meeting be held for the election of a new board of
directors of the company.

Pursuant to Section 5-7 (2) of the Norwegian Public Limited Liability
Companies Act, shareholders holding more than 5% of the share capital may
require that an extraordinary meeting is called for to address specified
matters. Such extraordinary general meeting shall be held within one month.
The Board of Directors will therefore call for an extraordinary general
meeting to be held no later than 11 March 2016.

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Further information

David Horn Solomon, President and CEO, +45 22 20 63 00, dhs@bionorpharma.com
Jens Krøis, CFO, +45 20 80 16 68, jk@bionorpharma.com
Jørgen Fischer Ravn, VP Investor Relations&Communications, +45 20 30 39 03,
jfr@bionorpharma.com

About Bionor

Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing
its proprietary therapeutic vaccine Vacc-4x in combination with other
medicines toward a functional HIV cure. The company believes it has first
mover potential based on clinical results to date and early adoption of now
recognized clinical strategy. In December 2015, Bionor announced that the HIV
'Shock&Kill' trial REDUC with Vacc-4x and romidepsin successfully met its
primary endpoint by significantly reducing latent HIV reservoir and further
demonstrated control of viral load. Bionor is currently planning BIOSKILL, a
proof-of-concept Phase II trial, which may lead to a major value inflection
point and partnering opportunities. Bionor currently retains full ownership
rights to Vacc-4x, i.e., the upside potential from partnering or licensing
remains with the company. Bionor is based in Oslo, Norway, and also has
offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo
Børs (OSE:BIONOR). More information about Bionor is available
atwww.bionorpharma.com.

Bionoor - request for EGM
http://hugin.info/131219/R/1985838/728404.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bionor Pharma ASA via Globenewswire

HUG#1985838

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.